Cardiac hypertrophy is a leading risk for
heart failure and
sudden death. Long non-coding RNAs (lncRNAs) have been implicated in a variety of human diseases, including
cardiac hypertrophy. We aimed to investigate the potential role and functional mechanism of
lncRNA metastasis-associated in
lung adenocarcinoma transcript 1 (MALAT1) in
cardiac hypertrophy. C57BL/6 mice underwent transverse aortic constriction (TAC) to induce
cardiac hypertrophy in vivo. The expression of MALAT1, miR-93-5p, and
sirtuin 4 (SIRT4)
mRNA was detected using a quantitative real-time polymerase chain reaction. The
protein levels of
cardiac hypertrophy-related markers, including
atrial natriuretic peptide (
ANP),
B-type natriuretic peptide (BNP) and β-
myosin heavy chain (β-MHC), and SIRT4 were measured via western blotting. The putative interaction between miR-93-5p and MALAT1 or SIRT4 was verified using a dual-
luciferase reporter assay,
RNA immunoprecipitation assay, or pull-down assay. Consequently, the expression of MALAT1 and SIRT4 was increased in TAC-treated mouse heart and
angiotensin II (Ang-II)-induced cardiomyocytes, whereas the expression of miR-93-5p was decreased. Ang-II promoted the expression of
ANP, BNP, and β-MHC and the surface area of cardiomyocytes, whereas MALAT1 downregulation impaired their expression and cell area. MiR-93-5p was a target of MALAT1, and its inhibition reversed the effects of MALAT1 downregulation. More importantly, MALAT1 modulated SIRT4 expression by degrading miR-93-5p. The expression of
ANP, BNP, and β-MHC suppressed by miR-93-5p restoration was recovered by SIRT4 promotion. Overall, MALAT1 knockdown ameliorated
cardiac hypertrophy partly by regulating the miR-93-5p/SIRT4 network, indicating that MALAT1 was a substantial
indicator of
cardiac hypertrophy.